FDA in the twenty-first century : the challenges of regulating drugs and new technologies / edited by Holly Fernandez Lynch and I. Glenn Cohen.
Saved in:
| Other Authors: | , |
|---|---|
| Other title: | Food and Drug Administration in the twenty-first century : the challenges of regulating drugs and new technologies. FDA in the 21st century. |
| Format: | Book |
| Language: | English |
| Published: |
New York :
Columbia University Press,
[2015]
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | lb643499 | ||
| 003 | CoU-L | ||
| 005 | 20220526051911.0 | ||
| 008 | 150112s2015 nyu b 001 0 eng | ||
| 010 | |a 2015001340 | ||
| 020 | |a 9780231171182 |q (hardcover ; |q alkaline paper) | ||
| 020 | |a 0231171188 |q (hardcover ; |q alkaline paper) | ||
| 035 | |a (OCoLC)900159170 | ||
| 035 | |a .b643499x |b lst1 |c - | ||
| 040 | |a DLC |b eng |e rda |c DLC |d YDX |d OCLCF |d YDXCP |d CDX |d GZL |d ILI |d YULAW |d UCX |d UtOrBLW | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 049 | |a UCXA | ||
| 082 | 0 | 0 | |a 363.19/20973 |2 23 |
| 090 | |a KF3871 |b .F328 2015 | ||
| 245 | 0 | 0 | |a FDA in the twenty-first century : |b the challenges of regulating drugs and new technologies / |c edited by Holly Fernandez Lynch and I. Glenn Cohen. |
| 246 | 3 | |a Food and Drug Administration in the twenty-first century : |b the challenges of regulating drugs and new technologies. | |
| 246 | 1 | 8 | |a FDA in the 21st century. |
| 264 | 1 | |a New York : |b Columbia University Press, |c [2015] | |
| 300 | |a xii, 551 pages ; |c 24 cm. | ||
| 336 | |a text |b txt |2 rdacontent. | ||
| 337 | |a unmediated |b n |2 rdamedia. | ||
| 338 | |a volume |b nc |2 rdacarrier. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Historical themes and developments at FDA over the past fifty years / Peter Barton Hutt -- A global and innovative regulatory environment for the U.S. FDA / Howard Sklamberg and Jennifer Devine -- FDA and the rise of the empowered patient / Lewis A. Grossman -- After the FDA : a twentieth-century agency in a postmodern world / Theodore W. Ruger -- The future of prospective medicine under the Food and Drug Administration Amendments Act of 2007 / Barbara J. Evans -- Global trends toward transparency in participant-level clinical trials data / Alla Digilova, Rebecca Li, Mark Barnes, and Barbara Bierer -- Conflicts of interest in FDA advisory committees : the paradox of multiple financial ties / Genevieve Pham-Kanter -- The crime of being in charge : executive culpability and collateral consequences / Katrice Bridges Copeland -- Recalibrating enforcement in the biomedical industry : deterrence and the primacy of protecting the public health / Patrick O'Leary -- Prospects for regulation of off-label drug promotion in an era of expanding commercial speech protection / Aaron S. Kesselheim and Michelle M. Mello -- The FDCA as the test for truth of promotional claims / Christopher Robertson -- Why FDA's ban on off-label promotion violates the First Amendment : a study in the values of commercial speech protection / Coleen Klasmeier and Martin H. Redish -- Speed versus safety in drug development / R. Alta Charo -- Overcoming "premarket syndrome" : promoting better postmarket surveillance in an evolving drug development context / Shannon Gibson and Trudo Lemmens -- FDA's Public Health Imperative : an increased role for active postmarket analysis / Efthimios Parasidis -- The drug efficacy study and its manifold legacies / Daniel Carpenter, Jeremy Greene, and Susan Moffitt -- Drug safety communication : the evolving environment / Geoffrey Levitt -- Innovation policy failures in the manufacturing of drugs / W. Nicholson Price II -- From "recycled molecule" to orphan drug : lessons from Makena / Kate Greenwood -- FDA, negotiated rule making, and generics : a proposal / Marie Boyd -- The "follow-on" challenge : statutory exclusivities and patent dances / Arti Rai -- FDA regulation of biosimilars / Henry Grabowski and Erika Lietzan -- Analog agency in a digital world / Nathan Cortez -- Twenty-first-century technology with twentieth-century baggage : FDA regulation of regenerative medicine / Margaret Foster Riley -- Device-ive maneuvers : FDA's risk assessment of bifurcated direct-to-consumer genetic testing / Elizabeth R. Pike and Kayte Spector-Bagdady -- A new regulatory function for e-prescriptions : linking FDA to physicians and patient records / Andrew English, David Rosenberg, and Huaou Yan -- Race and the FDA / Jonathan Kahn. | |
| 610 | 1 | 0 | |a United States. |b Food and Drug Administration. |
| 650 | 0 | |a Drugs |x Law and legislation |z United States. | |
| 610 | 1 | 7 | |a United States. |b Food and Drug Administration. |2 fast |0 (OCoLC)fst00549734. |
| 650 | 7 | |a Drugs |x Law and legislation. |2 fast |0 (OCoLC)fst00898830. | |
| 651 | 7 | |a United States. |2 fast |0 (OCoLC)fst01204155. | |
| 700 | 1 | |a Lynch, Holly Fernandez, |e editor. | |
| 700 | 1 | |a Cohen, I. Glenn, |e editor. | |
| 902 | |a 220722 | ||
| 999 | |b 1 |c 151027 |d m |e a |f - |g 0 | ||
| 994 | |a lst1 | ||
| 945 | |l lst1 | ||
| 999 | f | f | |i 27fc1b07-2bfd-515d-b122-c568823448b1 |s 793245fb-35e1-575a-8893-56fec32addbb |
| 952 | f | f | |p Can circulate |a University of Colorado Boulder |b Law Campus |c Law |d Law Library - Stacks 1st floor |e KF3871 .F328 2015 |h Library of Congress classification |i book |m U182004815229 |n 1 |